Florian Posch1, Lukas Leitner2, Marko Bergovec2, Angelika Bezan1, Michael Stotz1, Armin Gerger1, Martin Pichler1, Herbert Stöger1, Bernadette Liegl-Atzwanger3,4, Andreas Leithner2, Joanna Szkandera5. 1. Clinical Division of Medical Oncology, Department of Medicine, Comprehensive Cancer Center Graz, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria. 2. Department of Orthopedic Surgery, Comprehensive Cancer Center Graz, Medical University of Graz, Graz, Austria. 3. Center for Biomarker Research in Medicine, Medical University of Graz, Graz, Austria. 4. Institute of Pathology, Comprehensive Cancer Center Graz, Medical University of Graz, Graz, Austria. 5. Clinical Division of Medical Oncology, Department of Medicine, Comprehensive Cancer Center Graz, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria. joanna.szkandera@medunigraz.at.
Abstract
BACKGROUND: Exploration of the complex relationship between prognostic indicators such as tumor grade and size and clinical outcomes such as local recurrence and distant metastasis in patients with cancer is crucial to guide treatment decisions. However, in patients with soft tissue sarcoma, there are many gaps in our understanding of this relationship. Multistate analysis may help us in gaining a comprehensive understanding of risk factor-outcome relationships in soft tissue sarcoma, because this methodology can integrate multiple risk factors and clinical endpoints into a single statistical model. To our knowledge, no study of this kind has been performed before in patients with soft tissue sarcoma. QUESTIONS/PURPOSES: We implemented a multistate model of localized soft tissue sarcoma to statistically evaluate the relationship among baseline risk factors, recurrence, and death in patients with localized soft tissue sarcoma undergoing curative surgery. METHODS: Between 1998 and 2015, our center treated 539 patients for localized soft tissue sarcoma with surgery as curative intent. Of those, 96 patients (18%) were not included in this single-center retrospective study owing to missing baseline histopathology data (n = 3), not yet observed followup (n = 80), or because a neoadjuvant treatment approach in the presence of synchronous distant metastasis was used (n = 13), leaving 443 patients (82%) for the current analysis, of which 40 were lost to followup during the first year after surgery. All patients had tumors of the stages I to III according to the American Joint Committee on Cancer Stages. The median age of the patients was 62 years (range, 16-96 years), and 217 patients (49%) were female. Three hundred-forty-six patients (78%) had tumors of high grade (Grades 2 and 3), and 310 (70%) tumors were greater than 5 cm in maximum diameter. Patients who had died during the first year of followup were included in this analysis. Median followup for the 443 study patients was 6 years, with 84%, 52%, and 23% of patients being followed for more than 1, 5, and 10 years, respectively. The 15-year cumulative incidences of local recurrence, distant metastasis, and death from any cause, using a competing risk analysis, were 16% (95% CI, 11%-22%), 21% (95% CI, 17%-26%), and 55% (95% CI, 44%-67%), respectively. Wide resection with a margin of 1 mm was the preferred treatment for all patients, except for those with Grade 1 liposarcoma where a marginal resection was considered adequate. Multistate models were implemented with the mstate library in R. RESULTS: In multistate analysis, patients who experienced a local recurrence were more likely to have distant metastasis develop (hazard ratio [HR] = 8.4; 95% CI, 4.3-16.5; p < 0.001), and to die (HR = 3.4; 95% CI, 2.1-5.6; p < 0.001). The occurrence of distant metastasis was associated with a strong increase in the risk of death (HR = 12.6; 95% CI, 8.7-18.3; p < 0.001). Distant metastasis occurring after a long tumor-free interval was not associated with a more-favorable prognosis with respect to mortality than distant metastasis occurring early after surgery (estimated relative decrease in the adverse effect of distant metastasis on mortality for 1-year delay in the occurrence of distant metastasis = 0.9; 95% CI, 0.7-1.1; p = 0.28). High-grade histology (Grades 2 and 3) was associated with a higher risk of overall recurrence (defined as a composite of local recurrence and distant metastasis, HR = 3.8; 95% CI, 1.8-7.8; p = 0.0003) and a higher risk of death after recurrence developed (HR = 4.4; 95% CI, 1.1-18.2; p = 0.04). Finally, the multistate model predicted distinct outcome patterns depending on baseline covariates and how long a patient has remained free from recurrence after surgery. CONCLUSIONS: In patients with localized soft tissue sarcoma undergoing resection, the occurrence of local recurrence and distant metastasis contributes to a dramatically impaired long-term survival outcome. Local recurrences are a substantial risk factor for distant metastasis. Multistate modeling is a very powerful approach for analysis of sarcoma cohorts, and may be used in the future to obtain highly personalized, dynamic predictions of outcomes in patients with localized soft tissue sarcoma. LEVEL OF EVIDENCE: Level III, therapeutic study.
BACKGROUND: Exploration of the complex relationship between prognostic indicators such as tumor grade and size and clinical outcomes such as local recurrence and distant metastasis in patients with cancer is crucial to guide treatment decisions. However, in patients with soft tissue sarcoma, there are many gaps in our understanding of this relationship. Multistate analysis may help us in gaining a comprehensive understanding of risk factor-outcome relationships in soft tissue sarcoma, because this methodology can integrate multiple risk factors and clinical endpoints into a single statistical model. To our knowledge, no study of this kind has been performed before in patients with soft tissue sarcoma. QUESTIONS/PURPOSES: We implemented a multistate model of localized soft tissue sarcoma to statistically evaluate the relationship among baseline risk factors, recurrence, and death in patients with localized soft tissue sarcoma undergoing curative surgery. METHODS: Between 1998 and 2015, our center treated 539 patients for localized soft tissue sarcoma with surgery as curative intent. Of those, 96 patients (18%) were not included in this single-center retrospective study owing to missing baseline histopathology data (n = 3), not yet observed followup (n = 80), or because a neoadjuvant treatment approach in the presence of synchronous distant metastasis was used (n = 13), leaving 443 patients (82%) for the current analysis, of which 40 were lost to followup during the first year after surgery. All patients had tumors of the stages I to III according to the American Joint Committee on Cancer Stages. The median age of the patients was 62 years (range, 16-96 years), and 217 patients (49%) were female. Three hundred-forty-six patients (78%) had tumors of high grade (Grades 2 and 3), and 310 (70%) tumors were greater than 5 cm in maximum diameter. Patients who had died during the first year of followup were included in this analysis. Median followup for the 443 study patients was 6 years, with 84%, 52%, and 23% of patients being followed for more than 1, 5, and 10 years, respectively. The 15-year cumulative incidences of local recurrence, distant metastasis, and death from any cause, using a competing risk analysis, were 16% (95% CI, 11%-22%), 21% (95% CI, 17%-26%), and 55% (95% CI, 44%-67%), respectively. Wide resection with a margin of 1 mm was the preferred treatment for all patients, except for those with Grade 1 liposarcoma where a marginal resection was considered adequate. Multistate models were implemented with the mstate library in R. RESULTS: In multistate analysis, patients who experienced a local recurrence were more likely to have distant metastasis develop (hazard ratio [HR] = 8.4; 95% CI, 4.3-16.5; p < 0.001), and to die (HR = 3.4; 95% CI, 2.1-5.6; p < 0.001). The occurrence of distant metastasis was associated with a strong increase in the risk of death (HR = 12.6; 95% CI, 8.7-18.3; p < 0.001). Distant metastasis occurring after a long tumor-free interval was not associated with a more-favorable prognosis with respect to mortality than distant metastasis occurring early after surgery (estimated relative decrease in the adverse effect of distant metastasis on mortality for 1-year delay in the occurrence of distant metastasis = 0.9; 95% CI, 0.7-1.1; p = 0.28). High-grade histology (Grades 2 and 3) was associated with a higher risk of overall recurrence (defined as a composite of local recurrence and distant metastasis, HR = 3.8; 95% CI, 1.8-7.8; p = 0.0003) and a higher risk of death after recurrence developed (HR = 4.4; 95% CI, 1.1-18.2; p = 0.04). Finally, the multistate model predicted distinct outcome patterns depending on baseline covariates and how long a patient has remained free from recurrence after surgery. CONCLUSIONS: In patients with localized soft tissue sarcoma undergoing resection, the occurrence of local recurrence and distant metastasis contributes to a dramatically impaired long-term survival outcome. Local recurrences are a substantial risk factor for distant metastasis. Multistate modeling is a very powerful approach for analysis of sarcoma cohorts, and may be used in the future to obtain highly personalized, dynamic predictions of outcomes in patients with localized soft tissue sarcoma. LEVEL OF EVIDENCE: Level III, therapeutic study.
Authors: Alessandro Gronchi; Salvatore Lo Vullo; Chiara Colombo; Paola Collini; Silvia Stacchiotti; Luigi Mariani; Marco Fiore; Paolo Giovanni Casali Journal: Ann Surg Date: 2010-03 Impact factor: 12.969
Authors: Dario Callegaro; Rosalba Miceli; Sylvie Bonvalot; Peter Ferguson; Dirk C Strauss; Antonin Levy; Anthony Griffin; Andrew J Hayes; Silvia Stacchiotti; Cecile Le Pechoux; Myles J Smith; Marco Fiore; Angelo P Dei Tos; Henry G Smith; Luigi Mariani; Jay S Wunder; Raphael E Pollock; Paolo G Casali; Alessandro Gronchi Journal: Lancet Oncol Date: 2016-04-05 Impact factor: 41.316
Authors: Nisreen S Ezuddin; Juan Pretell-Mazzini; Raphael L Yechieli; Darcy A Kerr; Breelyn A Wilky; Ty K Subhawong Journal: Skeletal Radiol Date: 2018-05-21 Impact factor: 2.199
Authors: Maria Anna Smolle; Dimosthenis Andreou; Per-Ulf Tunn; Joanna Szkandera; Bernadette Liegl-Atzwanger; Andreas Leithner Journal: EFORT Open Rev Date: 2017-10-17
Authors: Christoph Schliemann; Andrea Kerkhoff; Paula Hesse; Sebastian Bröckling; Jendrik Hardes; Arne Streitbürger; Dimosthenis Andreou; Georg Gosheger; Sandra Elges; Eva Wardelmann; Wolfgang Hartmann; Rolf Mesters; Georg Lenz; Normann Willich; Jan Kriz; Hans Eich; Wolfgang E Berdel; Torsten Kessler Journal: PLoS One Date: 2018-05-22 Impact factor: 3.240
Authors: Angelika Terbuch; Jan B Adiprasito; Verena Stiegelbauer; Maximilian Seles; Christiane Klec; Georg P Pichler; Margit Resel; Florian Posch; Anna L Lembeck; Herbert Stöger; Joanna Szkandera; Karl Pummer; Thomas Bauernhofer; Georg C Hutterer; Armin Gerger; Michael Stotz; Martin Pichler Journal: Int J Mol Sci Date: 2018-10-12 Impact factor: 5.923
Authors: Florian Moik; Jakob M Riedl; Thomas Winder; Angelika Terbuch; Christopher H Rossmann; Joanna Szkandera; Thomas Bauernhofer; Anne-Katrin Kasparek; Renate Schaberl-Moser; Andreas Reicher; Felix Prinz; Martin Pichler; Herbert Stöger; Michael Stotz; Armin Gerger; Florian Posch Journal: Sci Rep Date: 2019-04-03 Impact factor: 4.379
Authors: Florian Posch; Karina Silina; Sebastian Leibl; Axel Mündlein; Holger Moch; Alexander Siebenhüner; Panagiotis Samaras; Jakob Riedl; Michael Stotz; Joanna Szkandera; Herbert Stöger; Martin Pichler; Roger Stupp; Maries van den Broek; Peter Schraml; Armin Gerger; Ulf Petrausch; Thomas Winder Journal: Oncoimmunology Date: 2017-12-18 Impact factor: 8.110
Authors: Maria Anna Smolle; Andreas Leithner; Florian Posch; Joanna Szkandera; Bernadette Liegl-Atzwanger; Martin Pichler Journal: Int J Mol Sci Date: 2017-09-12 Impact factor: 5.923
Authors: Florian Posch; Richard Partl; Carmen Döller; Jakob M Riedl; Maria Smolle; Lukas Leitner; Marko Bergovec; Bernadette Liegl-Atzwanger; Michael Stotz; Angelika Bezan; Armin Gerger; Martin Pichler; Karin S Kapp; Herbert Stöger; Andreas Leithner; Joanna Szkandera Journal: Ann Surg Oncol Date: 2017-09-11 Impact factor: 5.344